← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Xalud Therapeutics, Inc.
Berkeley, CA
$3,536,823
Total funding
2
Grants
Funding over time
peak $1.3M · FY2011–14$2M$1.5M$1M$500K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$3,536,823 · 2
By mechanism
U44$2,847,606 · 1
R43$689,217 · 1
Investigators at Xalud Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$996,485
U44 · FY2012 · NS
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$951,688
U44 · FY2013 · NS
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$383,748
U44 · FY2014 · NS
XT-101: A Potent IL-10 Based Therapy for Treating Multiple Sclerosis.$350,000
R43 · FY2014 · NS
XT-101: A Potent IL-10 Based Therapy for Treating Multiple Sclerosis.$339,217
R43 · FY2013 · NS
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$299,331
U44 · FY2011 · NS
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain$216,354
U44 · FY2014 · NS